NEW BRUNSWICK, N.J. / Aug 22, 2023 / Business Wire / Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 21st Annual Global Healthcare Conference at the Sheraton New York Hotel in New York on Wednesday, September 13th. Joaquin Duato, Chairman of the Board and Chief Executive Officer and John Reed, Executive Vice President Pharmaceuticals R&D will represent the Company in a session scheduled at 10:10 a.m. (Eastern Time).
This conference call will be available to investors and other interested parties by visiting the Johnson & Johnson website at www.investor.jnj.com.
A webcast and podcast replay will be available approximately 48 hours after the live webcast.
| Last Trade: | US$164.47 |
| Daily Change: | 0.37 0.23 |
| Daily Volume: | 3,728,032 |
| Market Cap: | US$396.370B |
October 15, 2024 October 15, 2024 September 30, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
